EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors

Anna K Anderson, André Lieber, Chang Li

Viruses · 2026

DOI: 10.3390/v18101078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2026. Verfasst von Anna K Anderson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle, WA 98195, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Genetic Vectors, Adenoviridae, Hematopoietic Stem Cells. Die Arbeit nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ex vivo hematopoietic stem cell (HSC) gene therapy strategies have proved effective for the treatment of various diseases, with recent advances leading to the clinical approval of several cell products. To overcome issues associated with the cost and technical complexity of ex vivo strategies, we turn towards in vivo strategies that will allow us to avoid myeloablative transplantation and broaden access. Advances in the engineering of adenoviruses have made them a promising platform for the targeted in vivo delivery of gene therapy vectors to HSCs. This narrative review highlights host barriers to in vivo HSC gene therapy using helper-dependent adenovirus vectors including innate and adaptive immune responses in the blood, virus uptake and sequestration by non-target cells and tissues, difficulty accessing the bone marrow niche, and the inefficient targeting of quiescent HSCs. We present recent advances aimed at overcoming these barriers including immune modulation and vector engineering strategies, improved predictive models, novel HSC targeting strategies, and enrichment of modified HSCs. This forward-looking review highlights a path towards achieving the clinical translation of predictable, safe and accessible in vivo adenovirus-mediated HSC gene therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyGenetic VectorsAdenoviridaeHematopoietic Stem CellsHelper VirusesHematopoietic Stem Cell TransplantationHumansAnimalsGene Therapy AgentsGene Transfer Techniques

Stichwörter der Autor:innen

bone marrowgene therapyhelper-dependent adenovirushematopoietic stem cellsimmune responsevector engineering

Autor:innen und Institutionen

  • Department of Medicine, University of Washington, Seattle, WA 98195, USA.
  • Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
  • State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.

Förderung

  • Bill & Melinda Gates Foundation
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • National Health Commission of the People's Republic of China
  • Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
  • NIH
  • Ensoma Bio
  • Bill and Melinda Gates Foundation

Zitieren

APA

Anderson, A. K., Lieber, A., & Li, C. (2026). Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors. Viruses. https://doi.org/10.3390/v18101078

Vancouver

Anderson AK, Lieber A, Li C. Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors. Viruses. 2026. doi:10.3390/v18101078

BibTeX
@article{Anderson2026,
  author = {Anderson, Anna K and Lieber, André and Li, Chang},
  title = {Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18101078}
}
Kostenlos starten →